Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
Chun‐Bing Chen, Ming-Ying Wu, Chau Yee Ng, et al.
Cancer Management and Research (2018) Vol. Volume 10, pp. 1259-1273
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Bryan J. Schneider, Jarushka Naidoo, Bianca Santomasso, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 36, pp. 4073-4126
Open Access | Times Cited: 585
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002435-e002435
Open Access | Times Cited: 568
Immune checkpoint inhibitor–related dermatologic adverse events
Amaris Geisler, Gregory S. Phillips, Dulce M. Barrios, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 5, pp. 1255-1268
Open Access | Times Cited: 347
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Lucie Heinzerling, Thomas Eigentler, Michael Fluck, et al.
ESMO Open (2019) Vol. 4, Iss. 3, pp. e000491-e000491
Open Access | Times Cited: 193
Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis
Natsumi Hama, Riichiro Abe, Andrew Gibson, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 5, pp. 1155-1167.e5
Open Access | Times Cited: 139
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin
Mario E. Lacouture, Anisha B. Patel, Jonathan E. Rosenberg, et al.
The Oncologist (2022) Vol. 27, Iss. 3, pp. e223-e232
Open Access | Times Cited: 90
Immune-related adverse events in various organs caused by immune checkpoint inhibitors
Naoko Okiyama, Ryota Tanaka
Allergology International (2022) Vol. 71, Iss. 2, pp. 169-178
Open Access | Times Cited: 86
Cutaneous manifestations associated with immune checkpoint inhibitors
Tomoya Watanabe, Yukie Yamaguchi
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 52
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management
Anastasiya Muntyanu, Elena Netchiporouk, William Gerstein, et al.
Journal of Cutaneous Medicine and Surgery (2020) Vol. 25, Iss. 1, pp. 59-76
Closed Access | Times Cited: 134
Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review
Olivia Charlton, Victoria Harris, Kevin Phan, et al.
Advances in Wound Care (2019) Vol. 9, Iss. 7, pp. 426-439
Open Access | Times Cited: 92
Updates and Insights in the Diagnosis and Management of DRESS Syndrome
Elisa M. Schunkert, Sherrie J. Divito
Current Dermatology Reports (2021) Vol. 10, Iss. 4, pp. 192-204
Open Access | Times Cited: 62
Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
Chieh‐Hsun Chen, Hsin‐Su Yu, Sebastian Yu
Current Oncology (2022) Vol. 29, Iss. 4, pp. 2871-2886
Open Access | Times Cited: 42
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
Yi-Shan Teng, Sebastian Yu
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6805-6819
Open Access | Times Cited: 25
Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review
Man Sun, Huan Zhou, Dan Zang, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access | Times Cited: 1
Erythema multiforme, Stevens‐Johnson syndrome/toxic epidermal necrolysis – diagnosis and treatment
Pavel Grünwald, Maja Mockenhaupt, Rüdiger Panzer, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2020) Vol. 18, Iss. 6, pp. 547-553
Closed Access | Times Cited: 61
Rituximab Hypersensitivity: From Clinical Presentation to Management
Ghada E. Fouda, Sevim Bavbek
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 58
Hypersensitivity reactions to biologicals: An EAACI position paper
Sevim Bavbek, Mauro Pagani, Emilio Alvarez‐Cuesta, et al.
Allergy (2021) Vol. 77, Iss. 1, pp. 39-54
Open Access | Times Cited: 46
Current Perspectives on Severe Drug Eruption
Jingzhan Zhang, Zixian Lei, Xu Chen, et al.
Clinical Reviews in Allergy & Immunology (2021) Vol. 61, Iss. 3, pp. 282-298
Open Access | Times Cited: 42
Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy
Alana Deutsch, Nicole R. LeBoeuf, Mario E. Lacouture, et al.
American Society of Clinical Oncology Educational Book (2020), Iss. 40, pp. 485-500
Closed Access | Times Cited: 47
Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors
Marissa A. Zarakas, Jigar V. Desai, Georgios Chamilos, et al.
Current Fungal Infection Reports (2019) Vol. 13, Iss. 3, pp. 86-98
Open Access | Times Cited: 42
The life-threatening eruptions of immune checkpoint inhibitor therapy
Emily Coleman, Brianna Olamiju, Jonathan S. Leventhal
Clinics in Dermatology (2019) Vol. 38, Iss. 1, pp. 94-104
Closed Access | Times Cited: 41
Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review
Ian T. Logan, Saman Zaman, Lama Hussein, et al.
Journal of Immunotherapy (2019) Vol. 43, Iss. 3, pp. 89-92
Closed Access | Times Cited: 38
Cutaneous immune-related adverse events to checkpoint inhibitors
Neeta Malviya, Ian Tattersall, Jonathan S. Leventhal, et al.
Clinics in Dermatology (2020) Vol. 38, Iss. 6, pp. 660-678
Closed Access | Times Cited: 34
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
Amy Musiek, Kerri E. Rieger, M. Bagot, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 29-40
Open Access | Times Cited: 32
Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China
Ruofei Du, Xin Wang, Lixia Ma, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top